This activity has been developed and designed for pharmacists who are preparing to sit for the Board of Pharmacy Specialty (BPS) exam in Psychiatric Pharmacy as they strive to obtain the credentials of Board Certified Psychiatric Pharmacist (BCPP).
Charles F. Caley, PharmD, BCPP
Clinical Professor | Chair
Western New England University
Springfield, MA
No Relevant Financial Relationships to Disclose
Ryan M. Carnahan, PharmD, BCPP, MS
Associate Professor
University of Iowa, College of Public Health, Epidemiology
Iowa City, IA
No Relevant Financial Relationships to Disclose
Jeremy Daniel, PharmD, BCPP, BCPS
Associate Professor of Pharmacy Practice
South Dakota State University College of Pharmacy and Allied Health Professions
Sioux Falls, SD
No Relevant Financial Relationships to Disclose
Sarah E. Grady, PharmD, BCPP, BCPS
Clinical Professor
Drake University
Des Moines, IA
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices.
Robin N. Hieber, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health & Clinical Pharmacy Lead
VISN 23 Clinical Resource Hub
IL
No Relevant Financial Relationships to Disclose
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
Consultant: Novus Medical Education, Pharmacy Times-Health Systems Edition
Speaker’s Bureau: Otsuka
Other Financial Support: Advisory Board-Sunovion, Boehrenger Ingelheim; Honoraria-Pharmacy Times, American College of Clinical Pharmacy
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: amphetamines, cabergoline, carbidopa/levodopa, clomipramine, clonidine, corticosteroids, diphenhydramine, gabapentin, melatonin, methadone, methylphenidate, mirtazapine, oxycodone, pregabalin, quetiapine, selegiline, trazodone, valerian, venlafaxine
Lindsey N. Miller, PharmD, BCPP
Clinical Pharmacist and Associate Professor
Lipscomb University and Vanderbilt Psychiatric Hospital
Nashville, TN
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Nearly all medications in this section are off-label
Sandra Mitchell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
VCU Health Systems
Richmond, VA
Consultant: Wolters-kluwer (Lexi-comp)
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: ADHD – bupropion, modafinil; ASD – haloperidol, fluphenazine, chlorpromazine, divalproex, N-acetylcysteine, amantadine, melatonin, omega-3 fatty acids, probiotics, zinc; Tics – risperidone, tiapride, sulpride, clonidine, guanfacine, olanzapine, quetiapine, ziprasidone, fluphenazine, botulinum toxin, metoclopramide, baclofen, levetiracetam, IVIG, NAC, nicotine, riluzole, d-serine, ondansetron, pramipexole, methylphenidate, desipramine; ODD/CD – antipsychotics, stimulants; Klinefelter’s – ZYN002
Carol A. Ott, PharmD, MPH, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
Indianapolis, IN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Project ECHO - Indiana University - Opioid Use Disorders - Expert Panelist, Tippecanoe County (Indiana) Public Defender's Office - case consultation, Psychopharmacology Consultation Team - Indiana University - Department of Child Services, Wolters-Kluwer/Lexi-Comp
Educational grants: SAMHSA
Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board, Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), NAMI West Central Indiana
Chris Paxos, BCGP, BCPP, BCPS
Professor, Pharmacy Practice
Northeast Ohio Medical University
Rootstown, OH
No Relevant Financial Relationships to Disclose
Kimberly B. Tallian, PharmD, BCPP, FASHP, FCCP*
Advanced Practice Pharmacist - Psychiatry
Scripps Mercy Hospital, San Diego, CA
San Diego, CA
Speaker's Bureau: San Diego Regional Center & San Diego Epilepsy Foundation
* This 2024-2025 Psychiatric Pharmacotherapy Review product is dedicated to the memory of Kim Tallian, PharmD, APH, BCPP, FASHP, FCCP, FCSHP, who passed away in January of 2023. Dr. Tallian has authored the Neurologic Disorders chapter for this product for the past decade, including this edition of the product. We are thankful to her for her lasting contributions to this product and AAPP.
Michele D. Thomas, PharmD, BCPP
Director of Pharmacy
Springfield Hospital Center
Sykesville, MD
No Relevant Financial Relationships to Disclose
Erika Titus-Lay, PharmD, BCPP, BCPS
Clinical Pharmacist
Kaiser Permanente
Sacramento, CA
Grant Support: ASHP Pharmacy Leadership Scholars Research Grant for $10,000
Andrew M. Williams, PharmD, BCPP
Supervising Clinical Pharmacist, Behavioral Health Pharmacies
Riverside University Health System
Riverside, CA
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Antipsychotics for Behavioral and Psychiatric Symptoms of Dementia
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures2024-2025 Editorial Board
Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists Lincoln, NE
No Relevant Financial Relationships to Disclose
Megan J. Ehret, PharmD, BCPP, MS
Professor
Associate Professor
Monrovia, MD
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Clayton D. English, PharmD, BCPS, BCPP, BCGP
Assistant Professor
University of Washington
Seattle, WA
Non-Financial Interests: Drug Utilization Review Board-Vermont State Medicaid, Board Member
Stephanie Nichols, PharmD, MPH, BCPP, BCPS, FCCP
Associate Professor of Pharmacy Practice
University of New England
Portland, ME
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: I am a member of the New England Public Advisory Council (affiliated with the Institute for Clinical and Economic Review)., I am a consultant for SAMHSA grant funded Opioid Response Network.
Educational Grants, Research Grants or Contracts: I am contracted as a subject matter expert for multiple Project ECHO communities in Northern New England that focus on OUD, AUD, and psychiatric conditions in older adults. These are hosted by the University of New Hampshire system., I am contracted as a SME for the Support for ME (Maine) SUD grant funded provider education and support program
Non-Financial Interests: Maine Independent Clinical Information Service Academic Detailing Advisory Committee, Member of the Maine's Gubernatorial Opioid Response Clinical Advisory Committee, Member of the Lunder-Dineen Time to Ask (about unhealthy drinking) Advisory Committee, Member of the Board of Directors of the Co-Occurring Collaborative Serving Maine, Member of the Maine Medical Professionals Health Program Advisory Committee, Chair of the Maine Prescription Monitoring Program Advisory Committee
Carol A. Ott, PharmD, MPH, BCPP
Clinical Professor of Pharmacy Practice
Purdue University/Eskenazi Health
Indianapolis, IN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Project ECHO - Indiana University - Opioid Use Disorders - Expert Panelist, Tippecanoe County (Indiana) Public Defender's Office - case consultation, Psychopharmacology Consultation Team - Indiana University - Department of Child Services, Wolters-Kluwer/Lexi-Comp
Educational grants: SAMHSA
Non-Financial Interests: Indiana Medicaid Drug Utilization Review (DUR) Board, Indiana Medicaid Mental Health Quality Advisory Committee (MHQAC), NAMI West Central Indiana
Chris Paxos, BCGP, BCPP, BCPS
Professor, Pharmacy Practice
Northeast Ohio Medical University
Rootstown, OH
No Relevant Financial Relationships to Disclose
All relevant relationships have been mitigated.
This BCPP prep product includes 11 recorded review webinars and one "last-chance" question and answer session with authors/presenters immediately before the Board of Pharmacy Specialties spring and fall testing windows.